Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
Interventions: bezuclastinib; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 35
States / cities: Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more

Conditions: Cold Urticaria
Interventions: Dupilumab SAR231893, Placebo, Non sedating H1-antihistamine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: San Diego, California • Boise, Idaho • Owensboro, Kentucky + 2 more

Conditions: Hereditary Angioedema (HAE)
Interventions: CINRYZE with rHuPH20; Biological
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 14 more

Conditions: Angioedema
Interventions: Icatibant, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sensitive Skin, Non-sensitive Skin
Interventions: Expert Clinical Grading, Instrumental Measurements, Parental Questionnaires, Biomarker Measurements; Other
Lead sponsor: Kenvue Brands LLC; Industry
Eligibility: 3 Months to 36 Months
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Dermatitis, Allergic Contact
Interventions: Patch Test; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Mineola, New York • Cincinnati, Ohio

Conditions: Hereditary Angioedema (HAE)
Interventions: DX-2930, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Atopic Dermatitis
Interventions: Roflumilast Cream 0.05%, Roflumilast Cream 0.15%, Vehicle Cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 17
States / cities: Scottsdale, Arizona • San Diego, California • Hialeah, Florida + 14 more

Conditions: Atopic Dermatitis
Interventions: Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab; Dietary Supplement · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 28
States / cities: Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more

Conditions: Allergic Rhinitis, Asthma, Food Allergy, Skin Testing
Interventions: Histamine skin testing; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: APG777, Placebo; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 29
States / cities: Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 40
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 65 Years
Enrollment: 111 participants
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis (AD)
Interventions: OTC Drug for Atopic Dermatitis in Cream form; Drug
Lead sponsor: Good Molecules, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 231 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Atopic Dermatitis
Interventions: YR001 ointment, Placebo; Drug · Other
Lead sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Boynton Beach, Florida • Hollywood, Florida • Weston, Florida + 1 more

Conditions: Sarcoidosis
Interventions: adalimumab; Drug
Lead sponsor: Pariser, Robert J., M.D.; Other
Eligibility: 18 Years to 89 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Atopic Dermatitis, Psoriasis
Interventions: YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area, YR001 Dose B on low body surface area, YR001 Dose B on middle body surface area, YR001 Dose B on high body surface area, Placebo on low body surface area, Placebo on middle body surface area, Placebo on high body surface area, YR001 Dose A on high body surface area twice daily, YR001 Dose B on high body surface area twice daily, Placebo on high body surface area twice daily; Drug
Lead sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions: XmAb7195, Placebo; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Urticaria
Interventions: Xolair® (Omalizumab); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 14
States / cities: Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more

Conditions: Dermatitis, Photoallergic
Interventions: Butenafine HCl 1% (BAY1896425) - Induction Phase, Butenafine HCl 1% (BAY1896425) - Challenge Phase; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Fairfield, New Jersey

Search by objective public record fields.

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

A Clinical Investigation Into the Association of an Impaired Skin Barrier and Infant and Toddler Sensitive Skin

Cutaneous and Systemic Reactions to Metal Implants

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Randomized Evaluation of Ten Allergy Skin Prick Test Devices

A Study Evaluating APG777 in Atopic Dermatitis

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

A Study of Adalimumab to Treat Sarcoidosis of the Skin

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Effect of Anti-IgE in Chronic Urticaria

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants